Open Innovation Drug Discovery

Biological Evaluation

OIDD investigators whose compound structures pass the in silico evaluation process are invited to submit compound samples for biological evaluation, which includes in vitro screening in Lilly active and emerging projects, neglected and tropical disease screening and possibly virtual screening when suitable models exist.

In Vitro Screening

In the in vitro screening process, each research module is composed of a primary screening assay, followed by relevant secondary biochemical and/or cell-based follow-up assays that further define the compound's biological activity profile and early potential for further optimization.

In vitro primary screening assays may be based on either phenotypic or target-based approaches. Phenotypic-based assays query complex cellular systems instead of specific targets. The target-based assays interrogate a well-validated target.

All results generated and relevant assay description details are provided directly to participating investigators through their personal OIDD accounts.

+

Neglected and Tropical Diseases Assay Modules

Besides accessing the Lilly OIDD biological assays, participating investigators are also provided results in a number of non-profit research modules for neglected and tropical diseases through Lilly's collaborations with global leaders in the fight to eradicate these diseases.

Virtual Screening

The OIDD Screening program offering provides continuous value to investigators by evaluating every submitted compound in as many biological modules as possible. This includes emerging projects of interest to Lilly. In fact, as long as Lilly has inventory, OIDD compound samples are routinely included in new biological screening modules as they become available.

Certain modules are based on in vitro primary assays which may have capacity constraints. In such cases, Lilly uses sophisticated in silico models to calculate a "score" representing the likelihood that a given compound will show activity on a certain target before going through the corresponding primary in vitro assay.

When available, these "virtual screening" scores are also provided to OIDD participants through their personal accounts, consistent with our standard cheminformatics protocols.

Biological Results

Following biological testing, all results are provided to participating investigators through their personal OIDD accounts. Participating investigators may export results to create personalized reports.

Data reported through the OIDD user interface include the single point (SP) of concentration at which the compound was tested in an assay to measure biological activity, plus the results associated with the subsequent concentration-response curve (CRC), where applicable. In addition, the exportable report includes molecular properties such as the atomic molecular weight (AMW), the measure of the compound's lipophilicity (cLogP), and heavy atom count (HA). More details regarding the display of biological results from the OIDD platform are available to participating investigators through their OIDD personal accounts.